Amgen acquires KAI pharmaceuticals

The acquisition, which was initially announced on 10 April 2012, includes KAI’s main product KAI-4169, an agent being studied to treat secondary hyperparathyroidism in patients with chronic kidney disease undergoing dialysis.

KAI in the past has submitted compelling Phase 2a clinical results for KAI-4169 in this indication.

KAI-4169 is administered intravenously to the Patients undergoing dialysis.

Amgen manufactures and develops therapeutics to help patients of cancer, kidney disease, rheumatoid arthritis, bone disease and other serious illnesses.

KAI Pharmaceuticals is a drug discovery and development company with multiple clinical-stage programs in the areas of cardiovascular disease, kidney disease and pain.